Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
08:00am, Thursday, 28'th Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ra
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
01:55pm, Monday, 25'th Aug 2025
NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
08:00am, Monday, 25'th Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Associatio
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
06:04am, Friday, 22'nd Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers feat
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
05:00am, Friday, 22'nd Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of its proprietary AI foundation model platform. These
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
06:00am, Monday, 18'th Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011
Natera shares surge 17% after strong Q2 results and upgraded guidance
04:08pm, Friday, 08'th Aug 2025
Shares of genetic testing company Natera (NASDAQ:NTRA) jumped sharply in morning trading, rising as much as 17% after the company reported better-than-expected second-quarter 2025 financial results an
Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
10:43pm, Thursday, 07'th Aug 2025
Natera, Inc. (NASDAQ:NTRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief Fi
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics
08:01pm, Thursday, 07'th Aug 2025
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
07:16pm, Thursday, 07'th Aug 2025
Natera (NTRA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.3 per share a year ago.
Natera (NTRA) Q2 Revenue Jumps 32%
05:54pm, Thursday, 07'th Aug 2025
Natera (NTRA) Q2 Revenue Jumps 32%
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
07:00am, Thursday, 07'th Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
07:00am, Friday, 01'st Aug 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transp
Natera to Report Its Second Quarter Results on August 7, 2025
07:00am, Thursday, 31'st Jul 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30,
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
07:00am, Tuesday, 29'th Jul 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the TEODOR trial (Neoadjuvant TrEatment Optimization
